Therapix Biosciences

Tel Aviv Stock Exchange: TRPX

$10.3m market cap

$2.96 last close

Therapix Biosciences is an Israeli pharmaceutical company developing two cannabinoids to treat Tourette syndrome and mild cognitive impairment. It is currently in Phase IIa and soon to begin Phase I, respectively, and owns or licenses several IPs for cannabinoid nasal and sublingual administration.

Investment summary

Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. Therapix recently announced the results of its Phase IIa study of THX-110 for the treatment of Tourette syndrome. The study showed a statistically significant (p=0.002) reduction in tic severity of 21%. The company also recently announced interim data of THX-110 in obstructive sleep apnea. Of the seven patients who completed the study, four exhibited significant improvements in endpoints such as reduction in Apnea-Hypopnea Index scale and the oxygen desaturation index, with one patient showing mild improvement. In July, the company announced a letter of intent to merge with Destiny Biosciences Global.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2015A N/A N/A N/A N/A N/A N/A
2016A 0.0 (1.7) (1.7) (179.9) N/A N/A
2017E 0.0 (4.0) (4.3) (118.4) N/A N/A
2018E 0.0 (7.7) (7.7) (200.1) N/A N/A
Last updated on 19/09/2019
Industry outlook

Diseases of the brain are a major unmet medical need with few effective or approved therapies for a host of diseases. Cannabinoids have had promising data in many indications in the area and is a class that has received a lot of interest.

Last updated on 19/09/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 9.8
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 23.1 15.4 (27.0)
Relative* 19.7 12.3 (29.4)
52-week high/low US$9.2/US$2.1
*% relative to local index
Key management
Elran Haber CEO
Josh Blacher CFO Designate